What question did this study set out to answer?

To characterize the immune landscapes of undifferentiated pleomorphic sarcoma (UPS) and myxofibrosarcoma (MFS) and examine their correlations with treatment response and prognosis.

July 2, 2025Cancer Immunology ImmunotherapyOpen Access

Divergent therapeutic and prognostic impacts of immunogenic features in undifferentiated pleomorphic sarcoma and myxofibrosarcoma

View Full Paper

Ask AI

Bookmark

Why the study?

To better understand the immunobiology of undifferentiated pleomorphic sarcoma and myxofibrosarcoma and its associations with treatment response and prognosis.

Does the immune microenvironment and neoadjuvant radiotherapy impact prognosis differently in undifferentiated pleomorphic sarcoma versus myxofibrosarcoma?

Population

Patients with UPS and MFS along with The Cancer Genome Atlas data (n = 206)

Comparison

UPS vs MFS

Design

Transcriptomic and immunophenotypic profiling study

Authors

SOSiddh van OostLeiden University Medical Center DMDebora M. MeijerLeiden University Medical Center ZEZeynep Betül ErdemLeiden University Medical Center

Discussion

Member takes

Implication

May support subtype-specific immune stratification in UPS/MFS trials; leaves open differential radiotherapy or immunotherapy responses.

Key Points

To characterize the immune landscapes of undifferentiated pleomorphic sarcoma (UPS) and myxofibrosarcoma (MFS) and examine their correlations with treatment response and prognosis.
Performed RNA sequencing on 13 UPS and 10 MFS tumors, benchmarking against The Cancer Genome Atlas soft tissue sarcoma dataset (n=206, including 44 UPS and 17 MFS).
Characterized immune cell contextures using imaging mass cytometry (14 UPS, 15 MFS) and evaluated T cell and macrophage infiltration via multispectral immunofluorescence and immunohistochemistry (23 UPS, 22 MFS).
Both sarcoma types displayed immunogenic traits, but UPS tumors exhibited higher myeloid cell infiltration compared to MFS.
Higher infiltration of T cells and CD68+CD163+ macrophages was significantly associated with improved metastasis-free survival in UPS, but no prognostic association was seen in MFS.
Neoadjuvant radiotherapy induced cytotoxic T cell infiltration and depleted myeloid cells specifically in UPS, while inducing no such immune alterations in MFS.

Structured PICO

Does the immune microenvironment and neoadjuvant radiotherapy impact prognosis differently in undifferentiated pleomorphic sarcoma versus myxofibrosarcoma?

Population

63 patients with soft tissue sarcomas, including 30 with undifferentiated pleomorphic sarcoma (UPS) and 33 with myxofibrosarcoma (MFS). The discovery cohort included 16 UPS and 17 MFS patients; the validation cohort included 23 UPS and 22 MFS patients.

Intervention

Neoadjuvant radiotherapy (evaluated in a subset of 13 UPS and 8 MFS cases with matched pre- and post-treatment samples)

Comparator

Myxofibrosarcoma (MFS) compared to Undifferentiated pleomorphic sarcoma (UPS), and pre-treatment vs. post-treatment samples

Outcome

Metastasis-free survival and disease-specific survival, as well as immune cell infiltration (T cells and macrophages)hard clinical

UPS and MFS exhibit distinct immunobiological features and divergent responses to neoadjuvant radiotherapy, suggesting that immunotherapeutic strategies should be tailored to the specific sarcoma subtype.

Cite This Study

Oost et al. (2025) studied this question.

synapsesocial.com/papers/6a70d67135aa2c282ce22964 https://doi.org/10.1007/s00262-025-04123-y

View Full Paper

Ask AI

Bookmark

Divergent therapeutic and prognostic impacts of immunogenic features in undifferentiated pleomorphic sarcoma and myxofibrosarcoma

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Divergent therapeutic and prognostic impacts of immunogenic features in undifferentiated pleomorphic sarcoma and myxofibrosarcoma

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Also Consider

Also Consider